FHA
CBAY

Flagship Harbor Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Flagship Harbor Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed – – 2003
2019
Q4 		$0 Hold
100
– – ﹤0.01% 1975
2019
Q3 		$0 Hold
100
– – ﹤0.01% 2000
2019
Q2 		$0 Hold
100
– – ﹤0.01% 2006
2019
Q1 		$1K Hold
100
– – ﹤0.01% 1798
2018
Q4 		$0 Hold
100
– – ﹤0.01% 2144
2018
Q3 		$1K Hold
100
– – ﹤0.01% 2036
2018
Q2 		$1K Buy
+100
New +$1.25K ﹤0.01% 1983

Other funds holding CBAY

ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Flagship Harbor Advisors's CBAY Position: Q1 2020 in Review

Flagship Harbor Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2020, closing a stake of 100 shares.

Flagship Harbor Advisors first reported a position in CBAY in Q2 2018 and held it in 7 quarters. The position peaked at $1K in Q1 2019. 102 funds tracked by Wall St. Rank hold CBAY as of Q1 2020.

  • Flagship Harbor Advisors reported no remaining Cymabay Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 100 Cymabay Therapeutics shares in Q1 2020.
  • Flagship Harbor Advisors first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 7 quarters.
  • Flagship Harbor Advisors's Cymabay Therapeutics position peaked at $1K in Q1 2019.
  • 102 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2020.

Based on Flagship Harbor Advisors's 13F filing for Q1 2020, filed 12 May 2020.